Fulcrum-Logo_Primary_Full-Color_RGB_Large.png
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 oct. 2024 16h30 HE | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 sept. 2024 16h30 HE | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
12 sept. 2024 06h55 HE | Fulcrum Therapeutics, Inc.
― Losmapimod failed to show an improvement in relative surface area (RSA), a measure of reachable workspace (RWS), versus placebo at week 48 ― ― Fulcrum to suspend future losmapimod development ― ―...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics to Participate in Upcoming September Conferences
27 août 2024 16h05 HE | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23 août 2024 16h30 HE | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
19 août 2024 07h00 HE | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 août 2024 16h30 HE | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
31 juil. 2024 07h00 HE | Fulcrum Therapeutics, Inc.
― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024 ― ― Entered into a collaboration and ex-U.S....
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
24 juil. 2024 08h00 HE | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
12 juin 2024 08h00 HE | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...